Search
DG-031 (formerly Bay x 1005)
Indications: (investigational uses)
1) treatment of asthma
2) reduction of risk factors for myocardial infarction
Dosage: 250-750 mg PO QD
Mechanism of action:
1) binds to & inhibits 5-lipoxygenase activating protein (FLAP)
2) prevents translocation of 5-lipoxygenase from the cytosol to membrane* also bound by 5 lipoxygenase
3) DG-013 reduces leukotriene B4 26%, myeloperoxidase 12% & C-reactive protein# 16% [1]
* perinuclear membrane? (see FLAP)
# not statistically significant [1]
Related
Arachidonate 5-lipoxygenase-activating protein; FLAP; MK-886-binding protein (ALOX5AP, FLAP)
General
unclassified molecule
Database Correlations
PUBCHEM cid=123723
References
- Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D,
Zink F, Andresdottir M, Manolescu A, Arnar DO, Andersen K,
Sigurdsson A, Thorgeirsson G, Jonsson A, Agnarsson U,
Bjornsdottir H, Gottskalksson G, Einarsson A, Gudmundsdottir H,
Adalsteinsdottir AE, Gudmundsson K, Kristjansson K, Hardarson T,
Kristinsson A, Topol EJ, Gulcher J, Kong A, Gurney M,
Thorgeirsson G, Stefansson K.
Effects of a 5-lipoxygenase-activating protein inhibitor on
biomarkers associated with risk of myocardial infarction:
a randomized trial.
JAMA. 2005 May 11;293(18):2245-56.
PMID: 15886380